The company said it will now investigate the formulation in a six-week hypertension study with multiple doses to explore its application to treat cardiovascular and other disease states beyond hypertension.
Lexaria shares were up 4.9% in recent trading.
Price: 1.72, Change: +0.09, Percent Change: +5.52
|--DCP Midstream Keeps Quarterly Distribution at $0.3...|
|Intel Likely to Top Q4 Sales Consensus, Raise 2022 O...|
|Customers Bancorp Reports Higher Q4 Core Earnings, R...|
|Crane Q4 Adjusted Earnings, Sales Gains Top Expectat...|
|-- Earnings Flash (CUBI) CUSTOMERS BANCORP Posts Q4 ...|